Adverse events associated with potential drugs for COVID-19: a case study from real-world data. Issue 2 (2nd October 2020)

• Record Type: Journal Article
• Authors: Jing, Ying; Diao, Lixia; Han, Leng
• Is Part Of: Briefings in bioinformatics. Volume 22:Issue 2(2021)
• Page Start: 1232
• Page End: 1238
• Publication Date: 2020-10-02
• Subjects: COVID-19 -- adverse events -- real-world data; Genetics -- Data processing -- Periodicals; Molecular biology -- Data processing -- Periodicals; Genomes -- Data processing -- Periodicals; 572.80285
• DOI: 10.1093/bib/bbaa234
• Languages: English
• ISSNs: 1467-5463

Abstract

Abstract: The coronavirus disease 2019 (COVID-19) has resulted as a global pandemic. The World Health Organization announced the most promising drugs in SOLIDARITY for the global trial, and several other drugs are under investigation through ongoing clinical trials to prove the effectiveness and safety of potential therapeutics. Here, we depicted the safety profile of these drugs and investigated their associated adverse events (AEs). We observed the associated AEs in different organs/systems, especially in skin and subcutaneous tissue, immune system and musculoskeletal and connective tissue. Furthermore, we observed strong bias of AEs in different groups of sex and age. Our study provides knowledge of the toxicity of potential COVID-19 drugs. While these drugs hold promise to fight the global pandemic, healthcare providers should pay attention to AEs to maximize the treatment benefit while minimizing toxicity.